Keyphrases
Percutaneous Coronary Intervention
100%
Acute Myocardial Infarction
51%
Myocardial Infarction
42%
Stent
40%
ST-elevation Myocardial Infarction (STEMI)
39%
Revascularization
39%
Drug-eluting Stent
35%
Acute Coronary Syndrome
35%
Clinical Outcomes
34%
Primary Percutaneous Coronary Intervention
33%
Confidence Interval
29%
Randomized Trial
28%
Intravascular Ultrasound
27%
Stent Thrombosis
24%
Dual Antiplatelet Therapy
21%
Paclitaxel-eluting Stent
20%
Hazard Ratio
18%
Adverse Cardiac Events
18%
Bivalirudin
18%
Coronary Artery Bypass Grafting
18%
Everolimus-eluting Stent
17%
Primary Angioplasty
17%
Bare Metal Stent
16%
Catheterization
15%
Triage Strategy
14%
Pooled Analysis
14%
Major Bleeding
14%
Meta-analysis
14%
Urgent Intervention
14%
Stent Implantation
13%
Taxus
13%
Ischemia
13%
Target Lesion Revascularization
12%
Clopidogrel
12%
Strategy Trials
12%
Left Main Coronary Artery
11%
Glycoprotein IIb/IIIa Inhibitors
11%
Angiography
11%
Bleeding
11%
Infarct Size
11%
Odds Ratio
11%
Target Vessel Revascularization
10%
All-cause Mortality
10%
Abciximab
10%
Excel
10%
Everolimus-eluting
10%
Heparin
10%
Coronary Artery Disease
10%
High Risk
9%
Randomized Controlled Trial
9%
Medicine and Dentistry
Percutaneous Coronary Intervention
91%
Myocardial Infarction
52%
Revascularization
43%
Acute Heart Infarction
41%
Drug-Eluting Stent
39%
Intravascular Ultrasound
36%
Coronary Artery Disease
33%
Acute Coronary Syndrome
29%
ST Segment Elevation Myocardial Infarction
28%
Primary Percutaneous Coronary Intervention
22%
Paclitaxel
22%
Everolimus
22%
Angioplasty
21%
Hazard Ratio
20%
Stent Thrombosis
19%
Coronary Artery Bypass Graft
18%
Congestive Heart Failure
18%
Antiplatelet
17%
Meta-Analysis
16%
Stenting
15%
Ischemia
14%
Mitral Insufficiency
14%
Coronary Artery
14%
Major Adverse Cardiac Event
14%
Catheterization
13%
Combination Therapy
13%
Angiography
13%
Target Lesion Revascularization
13%
Left Coronary Artery
12%
Restenosis
12%
Pooled Analysis
12%
Triage
12%
Infarction
12%
Cardiovascular System
12%
Bleeding
12%
Diabetes Mellitus
11%
Transluminal Coronary Angioplasty
10%
Disease
10%
Clinical Trial
10%
Odds Ratio
9%
Abciximab
9%
Target Vessel Revascularization
9%
Major Bleeding
9%
ST Elevation
9%
Randomized Controlled Trial
8%
Heart Muscle Revascularization
8%
Target Lesion
8%
Apoplexy
8%
Optical Coherence Tomography
8%
Adverse Event
8%